SCHEMBL2354075

SCHEMBL2354075

CC(C)(C)OC(=O)N1[C@@H](CO)CC[C@H]1c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 3/20 0.42
KCNK9 Q9NPC2 3/20 0.42
ABCB1 P08183 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
STS P08842 2/20 0.41
CNR1 P21554 1/20 0.40
FFAR2 O15552 1/20 0.40
RIPK1 Q13546 1/20 0.40
PDE5A O76074 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
APP P05067 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31134202 1.00 KCNK3 (0.42) KCNK3KCNK9ABCB1MEN1KMT2A
SCHEMBL14563127 0.87 TRPA1 (0.47) ABCB1MEN1KMT2AFFAR2
SCHEMBL14563128 0.87 TRPA1 (0.47) ABCB1MEN1KMT2AFFAR2
SCHEMBL2350570 0.87 TRPA1 (0.47) ABCB1MEN1KMT2AFFAR2
SCHEMBL30871755 0.87 RORC (0.42) KCNK3KCNK9ABCB1KMT2APDE5A
SCHEMBL475729 0.87 ABCB1 (0.52) ABCB1MEN1KMT2ARIPK1
SCHEMBL5149946 0.87 ABCB1 (0.52) ABCB1MEN1KMT2ARIPK1
SCHEMBL3857587 0.87 ABCB1 (0.52) ABCB1MEN1KMT2ARIPK1
SCHEMBL31134226 0.86 ALDH1A1 (0.46) ABCB1STSPDE5AALDH1A1HSD17B10
SCHEMBL2351859 0.84 FFAR2 (0.43) ABCB1MEN1KMT2AFFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125829-B1 BICYCLIC OXOMORPHOLINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2013-01-16 EP disclosed
US-8008293-B2 Bicyclic oxomorpholine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-08-30 US disclosed
US-20100113773-A1 BICYCLIC OXOMORPHOLINE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-05-06 US disclosed
US-20080207900-A1 TWO CYCLIC OXOMORPHORIN DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207900-A1 TWO CYCLIC OXOMORPHORIN DERIVATIVES OPRM1, OPRK1, OPRD1 KCNK3 1317/4885KCNK9 3453/4885ABCB1 1633/4885
US-20100113773-A1 BICYCLIC OXOMORPHOLINE DERIVATIVE OPRM1, OPRK1, OPRD1 KCNK3 512/4885KCNK9 1470/4885ABCB1 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.